Doug J Bartels

Author PubWeight™ 9.26^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.	Antimicrob Agents Chemother	2007	1.66
2	Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.	Clin Infect Dis	2013	1.62
3	Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.	J Biol Chem	2007	1.61
4	Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.	PLoS One	2012	1.19
5	Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples.	Virol J	2013	0.83
6	Characterization of V36C, a novel amino acid substitution conferring hepatitis C virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease.	Antimicrob Agents Chemother	2010	0.83
7	Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection.	Clin Gastroenterol Hepatol	2012	0.80
8	Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment.	Virol J	2012	0.75